| abstract |
The present invention provides novel serum stable lipid particles comprising one or more active or therapeutic agents, methods for producing the lipid particles, and methods for delivering and / or administering the lipid particles. More particularly, the invention relates to serum stable nucleic acid-lipid particles (SNALP) comprising nucleic acids (eg, one or more interfering RNA molecules), methods for producing SNALP, and SNALP (eg, for the treatment of cancer). Provides a method of delivering and / or administering. In certain aspects, the present invention provides tumor-directing lipid particles that preferentially target solid tumors. The tumor-directed preparation of the present invention can preferentially deliver a payload such as a nucleic acid to cells of a solid tumor as compared to non-cancerous cells. |